MedTrace Logo

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

NCT07053917 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-02-13

No results posted yet for this study

Summary

The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.

Conditions

  • Stroke
  • Chronic Stroke
  • Intracerebral Haemorrhage
  • Intracerebral Haemorrhage (ICH)
  • Intracerebral Hemorrhage Basal Ganglia
  • Ischemic Stroke
  • Ischemic Stroke and Hemorrhagic Stroke
  • Hemiparesis After Stroke
  • Hemiplegia Following Ischemic Stroke
  • Hemiplegia and Hemiparesis
  • Hemiplegia and/or Hemiparesis Following Stroke
  • Middle Cerebral Artery Stroke

Interventions

DRUG

Psilocybin (Usona Institute)

Participants will receive psilocybin to test its safety. Secondary outcomes will assess recovery from post-stroke deficits.

Sponsors & Collaborators

Principal Investigators

  • Victor Urrutia, M.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-09
Primary Completion
2027-02-28
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07053917 on ClinicalTrials.gov